Skip to main content
Premium Trial:

Request an Annual Quote

Affymetrix, Riken, Oligos Etc., and Accelr8 Technology

Premium

Affymetrix of Santa Clara, Calif., has received US Patent No. 6,844,433, “Nucleic acid labeling compounds.” The patent covers nucleic acid labeling compounds containing heterocyclic derivatives, which are synthesized by condensing a heterocyclic derivative with a cyclic group (e.g. a ribofuranose derivative). The labeling compounds are suitable for enzymatic attachment to a nucleic acid, either terminally or internally, to provide a mechanism of nucleic acid detection.


Riken of Saitama, Japan, has received US Patent No. 6,844,185, “Integrated biomolecule sensor, method and apparatus for fabricating the sensor, and method and apparatus for detecting biomolecules using the sensor.” The patent covers an integrated biomolecule sensor comprising a plurality of optical fibers whose proximal ends are held together with the end-faces arranged substantially in the same plane and oriented substantially in the same direction, and which have probe polymers with different base sequences bound to the core end-face at their distal ends. The method and apparatus for fabricating the integrated biomolecule sensor, and the method and apparatus for detecting biomolecules using the integrated biomolecule sensor are also disclosed. Researchers can make their own sensors best suited for individual requirements, and detect the presence of target biomolecules quickly, without need of expensive equipment.


Oligos Etc. of Wilsonville, Ore., has received US Patent No. 6,844,151, “Methods for production of arrays with modified oligonucleotide and polynucleotide compositions.” The invention provides methods for producing arrays having associated modified nucleic acid structures, e.g. acid stable and/or end-blocked nucleic acids. In one embodiment, arrays produced using the methods of the invention exhibit an increased binding affinity with complementary nucleic acids, and in particular with complementary RNA. In another embodiment, the associated nucleic acids of the array produced using the methods of the invention exhibit substantial acid resistance, allowing the arrays to be treated with low pH solutions. In another embodiment, the modified associated nucleic acids of the array produced using the methods of the invention exhibit substantial resistance to nuclease degradation.


Accelr8 Technology of Denver has received US Patent No. 6,844,028, “Functional surface coating.” The patent covers compositions and methods of preparing functional thin films or surface coatings with low non-specific binding. The thin films contain specified functional groups and non-specific binding repellant components. The thin films are either covalently bound to or passively adsorbed to various solid substrates. The specified functional group provides specified activity for the thin-film modified solid surfaces, and non-specific binding repellant components significantly reduce the non-specific binding to the thin-film modified solid surfaces. Surface coatings are also described having both non-specific protein binding properties combined with functional groups for specific binding activity, thereby providing surface coating that specifically recognize target proteins but limit binding to non-specific proteins.

The Scan

Study Tracks Off-Target Gene Edits Linked to Epigenetic Features

Using machine learning, researchers characterize in BMC Genomics the potential off-target effects of 19 computed or experimentally determined epigenetic features during CRISPR-Cas9 editing.

Coronary Artery Disease Risk Loci, Candidate Genes Identified in GWAS Meta-Analysis

A GWAS in Nature Genetics of nearly 1.4 million coronary artery disease cases and controls focused in on more than 200 candidate causal genes, including the cell motility-related myosin gene MYO9B.

Multiple Sclerosis Contributors Found in Proteome-Wide Association Study

With a combination of genome-wide association and brain proteome data, researchers in the Annals of Clinical and Translational Neurology tracked down dozens of potential multiple sclerosis risk proteins.

Quality Improvement Study Compares Molecular Tumor Boards, Central Consensus Recommendations

With 50 simulated cancer cases, researchers in JAMA Network Open compared molecular tumor board recommendations with central consensus plans at a dozen centers in Japan.